Glenmark begins Phase III trials of favipiravir for Covid-19 in India

13th May 2020 (Last Updated May 13th, 2020 07:30)

India-based Glenmark Pharmaceuticals has started Phase III clinical trials of anti-flu drug favipiravir as a potential treatment for patients suffering from Covid-19 in the country.

More than ten government and private hospitals in India are being recruited for the trial.